Bausch Health Companies Inc. (BHC)

Market Cap	2.01B +14.0%
Revenue (ttm)	10.53B +8.2%
Net Income	-1.21B
EPS	-3.25
Shares Out	373.48M
PE Ratio	n/a
Forward PE	1.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,806,820
Open	5.42
Previous Close	5.40
Day's Range	5.38 - 5.61
52-Week Range	4.41 - 8.69
Beta	0.42
Analysts	Hold
Price Target	7.50 (+39.15%)
Earnings Date	Apr 29, 2026

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,300
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Analyst Summary

According to 9 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $7.5, which is an increase of 39.15% from the latest price.

Price Target

$7.5

(39.15% upside)

Analyst Consensus: Hold